This ADC product is comprised of an anti-CD248 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CD248; CD248 molecule, endosialin; CD164 sialomucin like 1 , CD164L1, CD248 antigen, endosialin; endosialin; TEM1; tumor endothelial marker 1; 2610111G01Rik; CD164 sialomucin-like 1; CD248 antigen, endosialin; CD164L1; MGC119478; MGC119479;
- Target Entrez Gene ID
- 57124
- Overview
- CD248 (CD248 Molecule) is a Protein Coding gene. GO annotations related to this gene include calcium ion binding and extracellular matrix binding. An important paralog of this gene is CD93.
ADC Antibody
- Overview
- Chimeric/humanized hybrid Anti-CD248 IgG1-kappa antibody, Ontuxizumab
ADC Linker
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products